H ypertensive disorders occur in nearly 10% of pregnancies and carry increased risk of complications; preeclampsia in particular predisposes to eclampsia, a life-threatening condition, and is associated with increased maternal and perinatal mortality.
1,2 Preeclamptic women often need intensive monitoring and treatment, requiring the involvement of a multidisciplinary care team.
Altered vascular placental function has been recognized as an important mechanism leading to preeclampsia. 3 However, vascular dysfunction is not limited to the placenta, but involves the entire cardiovascular system and it is associated with adverse cardiovascular events years after pregnancy despite normalization of arterial blood pressure. 4, 5 Several studies have shown alterations of the maternal cardiovascular system during hypertensive disorders of pregnancy, suggesting reduced arterial compliance. [6] [7] [8] Although several noninvasive techniques are available to evaluate arterial elastic properties, the assessment of arterial compliance by radial artery waveform analysis allows one to distinguish between large (C1) conduit and small (C2) microcirculatory artery elasticity. 9 C1 and C2 decrease with advancing age and diabetes in nonpregnant subjects. 10 ,11 C2 levels, but not C1, are affected by nitric oxide (NO) bioavailability, as evidenced by the reduction of C2 in healthy volunteers receiving NO synthase inhibitors 12, 13 and in patients affected by diseases characterized by reduced NO bioavailability, such as coronary artery disease and hypertension. 14, 15 Previous reports showed that reduced NO bioavailability occurs in women affected by hypertensive disorders of pregnancy and possibly has a pathogenic role. 16, 17 The assessment of C2 may help to elucidate the effects of reduced NO bioavailability on arterial compliance. Moreover, C2 may be useful to detect vascular alterations leading to proteinuria and therefore preeclampsia, as suggested by the finding that C2 is reduced when microalbuminuria is present. 18 The early identification of preeclampsia may allow for surveillance of symptoms and implementation of strategies to prevent major complications.
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BACKGROUND: Vascular alterations are present in pregnant women affected by preeclampsia. In this study, we assessed arterial compliance in women affected by hypertensive disorders of pregnancy. We hypothesized that arterial compliance is reduced in women affected by preeclampsia. METHODS: Forty-three hypertensive pregnant women undergoing evaluation for preeclampsia were studied. Clinical data about each patient and pregnancy were collected. Large (C1) and small (C2) artery compliance were assessed by radial tonometry, while the patients underwent laboratory tests to diagnose preeclampsia. At the time of delivery, gestational age and newborn data were recorded. RESULTS: Eighteen women were diagnosed with preeclampsia. C2 levels were lower among preeclamptic versus hypertensive aproteinuric women (mean ± SD, 4.5 ± 1.3 vs 5.9 ± 2.3 mL/mm Hg · 100, P = 0.013, 95% confidence interval [CI] of difference 0.32-2.55), whereas C1 levels did not differ. In the preeclampsia group, C2 levels correlated with urine total protein concentrations measured the same day (Spearman ρ = −0.49, P = 0.047, upper 95% CI −0.01) and with gestational age at first occurrence of hypertension (Spearman ρ = 0.59, P = 0.010, lower 95% CI 0.17). Among singleton gestations, C2 also correlated with newborn birth weight measured at delivery (Spearman ρ = 0.43, P = 0.009, lower 95% CI 0.11). Women who were hypertensive but aproteinuric at the time of compliance assessment, but who subsequently developed preeclampsia (n = 6), had C2 levels similar to those with an early diagnosis of preeclampsia (mean difference 0.37 mL/mm Hg · 100, 95% CI −2.42 to 1.67) and lower C2 levels than women diagnosed with gestational hypertension (P = 0.019, 95% CI 0.33-4.42 mL/mm Hg · 100). CONCLUSIONS: The noninvasive assessment of arterial elasticity may contribute toward characterization of the nature of the pathophysiology in pregnancy-induced hypertensive disorders. The vascular alterations of the small arteries, as assessed by C2, may reflect the extent of vascular alterations present with preeclampsia. (Anesth Analg 2013;116:1050-56) Therefore, we investigated C1 and C2 with a noninvasive and operator-independent tonometric technique in a population of hypertensive pregnant women. We considered only hypertensive disorders occurring de novo during pregnancy, defining preeclampsia as the onset of hypertension after the 20th gestational week associated with proteinuria. 20 We hypothesized that C2 (primary end point) is lower in preeclamptic compared with hypertensive but aproteinuric women, reflecting more extensive microcirculatory alterations. We also hypothesized that C2 correlates with markers of severity of the disease, such as degree of proteinuria, early onset of hypertension during pregnancy, and increased systemic vascular resistance (SVR).
METHODS
All procedures were approved by the Partners' IRB, and enrolled subjects provided written informed consent.
Subjects
We enrolled 43 pregnant women with de novo hypertension (systolic blood pressure ≥140 or diastolic ≥90 mm Hg for 2 consecutive measurements more than 6 hours apart after the 20th week of gestation) referred to our tertiary care center for evaluation of the possible presence of preeclampsia. Study subjects were enrolled when the investigators were available. Women with known preexisting diseases such as diabetes mellitus, hypertension, or renal disease were excluded. At the time vascular measurements were made for the study, women were not yet receiving any medications for arterial blood pressure control.
Arterial Compliance Measurement
Upon enrollment, C1 and C2 values were assessed by using the HDI/Pulsewave CR-2000 instrument (Hypertension Diagnostics, Inc., Eagan, MN). The use of this instrument and the principles underlying the arterial compliance measurements have been previously described.
14 Briefly, a tonometric sensor applied over the radial artery recorded pulse waveforms while the patient was in the supine position with left uterine displacement. After a 30-second measurement, a beat-marking algorithm determined the beginning of systole and diastole. The diastolic portion of the pulse wave was analyzed using a modified Windkessel model, 9 resulting in calculation of the capacitative compliance (due to large arteries), the oscillatory compliance (due to small arteries), the blood volume inertia, and the SVR. Noninvasive arterial blood pressure was measured concurrently. The noninvasive assessment of arterial compliance and SVR relies on a parameter-estimating algorithm integrating data obtained from the analysis of pulse waveforms and the cardiac output, considering age, height, weight, and gender of the study subjects. 14 
Data Collection and Preeclampsia Diagnosis
At enrollment, blood pressure data from antenatal visits and laboratory data were evaluated. Analysis of blood and urine samples was performed to establish the diagnosis of preeclampsia and to calculate the Preeclampsia Integrated Estimate of Risk (PIERS) score (related to adverse maternal outcomes). 21 A diagnosis of preeclampsia was made if proteinuria (>300 mg/24 hours) was present. When a 24-hour urine collection was not feasible, a protein-to-creatinine ratio value ≥0.3 was considered diagnostic for presence of proteinuria. 22 Criteria for severe preeclampsia included preeclampsia occurring before the 35th week of gestational age, blood pressure >160/110 mm Hg, and proteinuria >5 g/24 hours.
We also recorded descriptive data for each woman (age, parity, history of preeclampsia in a previous pregnancy, and body mass index in the first trimester) and for the pregnancy (maximum systolic and diastolic blood pressure, number of fetuses, gestational age at which hypertension was first documented with a single measurement, and gestational age at study enrollment).
At delivery, we recorded gestational age, birth weight, gender of the newborn, Apgar score at 1 minute (for nonsingleton fetuses, the lower score of the neonates was used for analysis), type of delivery, and percentile of placental weight for gestational age assessed at the pathology examination.
The diagnosis of gestational hypertension was made in retrospect, in the absence of proteinuria and other laboratory abnormalities characteristic of preeclampsia and with normalization of blood pressure within 12 weeks after delivery. Women who met diagnostic criteria for preeclampsia later than 24 hours after enrollment were classified as "pending preeclampsia."
Statistical Analysis
Considering the exploratory nature of the study and the lack of preliminary data regarding arterial compliance in pregnant women with or without preeclampsia, we based our sample size estimation on other explorative studies investigating differences in C2 between different groups of patients or different treatments. 13, 14 We reasoned that a sample size of approximately 20 patients per group (hypothesizing a difference in C2 of 3 units and standard deviation of 4) would suffice to obtain a power of nearly 90% for an α value of 0.05.
Continuous variables are reported as mean ± SD. Normality of variable distribution was evaluated using the Lilliefors test (all P > 0.069). Comparison of characteristics between preeclamptic and hypertensive but aproteinuric women was performed using the t test and Mann-Whitney analysis for normally distributed variables and nonparametric variables, respectively. The Fisher exact test was used for comparison of categorical variables. The correlation coefficient between nonnormally distributed variables was calculated using Spearman correlation coefficient. Confidence intervals (CIs) for correlation coefficients were computed based on Fisher transformation. We performed receiver operating characteristic (ROC) curve analysis to evaluate the predictive value of C1 and C2 levels for the diagnosis of preeclampsia. Confidence limits were calculated for the area under the ROC curve using the Hanley method (available in Stata). Crossvalidation was used to calculate the CIs for the sensitivity and specificity estimates and CIs in an effort to avoid overfitting our model given the small size of our dataset. The "Leave one out" Crossvalidation was performed using the Stata program crossval.ado. 
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To evaluate predictors of preeclampsia, multivariate logistic regression modeling was performed. In addition to C2, the following known risk factors for preeclampsia were included in the model: age, nulliparity, and history of preeclampsia. Age (>40 or <18 years), as well as nulliparity and history of preeclampsia, were coded as dichotomous variables. No significant interactions were present among tested predictors (all P > 0.13).
Comparisons of the mean values of arterial compliance between multiple groups (preeclampsia, gestational hypertension, and pending preeclampsia group) were performed using the analysis of variance test; Tukey's post hoc test was performed to adjust for multiple comparisons. Statistical analyses were performed using SPSS software version 18.0 (SPSS Inc., Chicago, IL) and STATA 10 (StataCorp 2007; StataCorp, College Station, TX). Statistical significance was reached at P < 0.05.
RESULTS
Among the 43 hypertensive pregnant women enrolled, preeclampsia was diagnosed in 18 (42%). Among preeclamptic women, severe preeclampsia was diagnosed in 7 (39%). Age, incidence of nulliparity, known preeclampsia in a previous pregnancy, body mass index during the first trimester, maximum systolic or diastolic blood pressure, and number of singleton pregnancies did not differ between preeclamptic and hypertensive but aproteinuric women ( Table 1) . The increase in blood pressure tended to occur earlier in pregnancy in the preeclampsia group, but the difference did not reach statistical significance (P = 0.078).
Arterial Compliance and Preeclampsia
C2 was lower in women affected by preeclampsia compared with hypertensive but aproteinuric women at the time of arterial compliance assessment (4.5 ± 1.3 vs 5.9 ±2.3 mL/ mm Hg · 100, P = 0.013, 95% CI of difference 0.32-2.55) ( Fig.  1 and Table 2 ), whereas C1 levels did not differ (95% CI of difference −1.53 to 3.28 mL/mm Hg · 100). The ROC curve analysis showed that C2 levels, but not C1, might be useful in discriminating preeclamptic from hypertensive but aproteinuric women (area under the curve 0.68, P = 0.044 [95% CI 0.52-0.84] and 0.59, P = 0.32, respectively). Considering only the 18 nulliparous women, the ROC curve analysis showed an association between preeclampsia and C2 values, but not C1 (area 0.86, P = 0.009 [95% CI 0.68-0.98] and area 0.76, P = 0.058, respectively; Fig. 2) . A C2 cutoff of 4.5 mL/mm Hg • 100 predicted preeclampsia with 71% sensitivity (95% CI 50%-87%) and 61% specificity (95% CI 36%-82%) in the entire population, and 75% sensitivity (95% CI 36%-96%) and 78% specificity (95% CI 40%-96%) in the subgroup of nulliparous women.
To investigate possible predictors of preeclampsia, including C2, a logistic regression was performed. Age >40 or <18 years, nulliparity, known preeclampsia in a previous pregnancy, and C2 were included in the analysis as predictors of preeclampsia. Among these possible predictors, C2 was the only independent predictor associated with preeclampsia (P = 0.032, odds ratio 0.65 per C2 unit increase, 95% CI 0.44-0.96).
Of the 25 aproteinuric women at the time of arterial compliance assessment, at follow-up, 19 were diagnosed with gestational hypertension while 6 later developed preeclampsia. Retrospective analyses showed that C2 assessed at enrollment was lower both in women with preeclampsia and women who later developed preeclampsia, as compared with women affected by gestational hypertension (P = 0.004 and P = 0.019 respectively, P = 0.002 by analysis of variance; Fig. 3 ). C1 levels did not differ among the groups (P = 0.90).
Arterial Compliance and Clinical Variables at Enrollment
In the preeclampsia group, but not among women without preeclampsia at enrollment, C2 levels correlated with urine total protein concentrations (Spearman ρ = −0.49, P = 0.047) and with gestational age at first occurrence of hypertension (Spearman ρ = 0.59, P = 0.010). C2 and C1 inversely correlated with SVR in the preeclampsia patients (Spearman ρ = −0.63, P = 0.005 and Spearman ρ = −0.64, P = 0.005, respectively), but not in hypertensive but aproteinuric women.
Arterial Compliance and Clinical Parameters at Delivery
On average, patients delivered 1.0 ± 1.6 week after enrollment. Among these hypertensive patients (preeclamptic and hypertensive but aproteinuric women), C2 measured at enrollment was lower in parturients who subsequently gave birth to newborns with a lower Apgar score at 1 minute (P = 0.026, 4.6 ± 1.5 for newborns with Apgar score ≤8 vs 6.0 ± 2.4 for newborns with Apgar score >8). Considering only singleton neonates, C2 also correlated with newborn birth weight (Spearman ρ = 0.43, P = 0.004) but not placental weight. Women delivering within 24 hours of enrollment had higher PIERS score (P = 0.009, 1.1% ± 0.9% vs 0.6% ± 0.5%), whereas the PIERS score at enrollment did not correlate with C2 or C1 either in preeclamptic or hypertensive but aproteinuric women (all P > 0.49).
DISCUSSION
In this study, we report that small artery compliance levels (C2) are lower in hypertensive pregnant women diagnosed with preeclampsia compared with those without proteinuria. In women affected by preeclampsia, reduced C2 levels correlate with severity of disease, as expressed by proteinuria, SVR, and earlier onset of hypertension during pregnancy. We could not locate other studies investigating C2 and vascular dysfunction during hypertensive disorders of pregnancy for comparison. To reduce confounding factors, we excluded women with preexisting diseases, such as pregestational hypertension or diabetes, and women affected by conditions that could influence the diagnosis of preeclampsia, such as renal disease. We included women with multiple gestations because of the increased risk of hypertensive disorders of pregnancy in this group. We could not locate published reports of C2 levels measured during normal pregnancy. We did not measure C2 in a matched group of healthy pregnant women because the aim of this study was to investigate a possible difference in arterial compliance levels between preeclamptic and hypertensive but aproteinuric women. A reliable assessment of arterial Receiver operating characteristic curve for assessment of the sensitivity and specificity of large (C1) and small (C2) artery compliance levels in predicting preeclampsia in the subgroup of 18 hypertensive nulliparous women. P = 0.009 and P = 0.058 for C2 and C1, respectively.
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Arterial Compliance in Hypertension of Pregnancy compliance in nonhypertensive pregnant women, matched for years of age and gestational ages, would have required many more subjects than was feasible for this study. To our knowledge, this information has not yet been published and is an area for further investigation.
In our population of pregnant women with new-onset hypertension, C2 was markedly lower (approximately 35%) in comparison to previously published data from healthy nonpregnant women (5.3 ± 2.0 vs 8.1 ± 2.3 mL/mm Hg · 100 average C2 levels, respectively), 23 and was similar to levels measured in postmenopausal women affected by coronary artery disease (5.1 mL/mm Hg · 100 average C2 levels). 14 The vasorelaxation state typical of healthy pregnancies is lacking in gestational hypertension and preeclampsia, as evidenced by the presence of hypertension. 24, 25 The finding that C2 is lower in the presence of preeclampsia suggests that the noninvasive assessment of arterial compliance may reflect the severity of the systemic vascular dysfunction during hypertensive disorders of pregnancy.
Despite the novel results of this study, our data are not sufficient to support a routine C2 assessment to discriminate preeclampsia and gestational hypertension in the clinical setting. The small number of patients and the assessment of compliance at different gestational ages may have contributed. Another possible reason is that preeclampsia and gestational hypertension might represent different levels of severity of the same disease, and therefore be difficult to distinguish. 26, 27 Moreover, the inclusion of nulliparous and parous women might be a confounding factor. Although uric acid levels are not useful in the diagnosis of preeclampsia in a general population of pregnant women, 28 they seemed to be a reliable predictor of preeclampsia in a selected population of nulliparous women referred for newonset hypertension in pregnancy. 29 As these and our findings suggest, the clinical relevance of C2 assessment might be more pronounced in the group of nulliparous women; however, more data are needed to confirm this hypothesis.
Although our data are limited, it is intriguing to hypothesize a potential role for C2 levels to exclude preeclampsia. A value of C2 >6.2 mL/mm Hg · 100 provides 44% sensitivity and 95% specificity for excluding preeclampsia; in the nulliparous population, sensitivity is 47% and specificity 100%. Another possible role for C2 levels is the identification of women at risk of developing preeclampsia when diagnostic criteria are not yet present. We used retrospective follow-up data analysis for 2 purposes: to identify hypertensive women without criteria of preeclampsia at the moment of arterial compliance assessment but who subsequently developed preeclampsia, and to confirm a posteriori the diagnosis of gestational hypertension. Although the sample size is small, C2 levels in the "pending preeclampsia" group are similar to those measured in the preeclamptic group and are lower compared with the gestational hypertension group. This is consistent with the hypothesis that C2 is related to the underlying vascular disease leading to clinical manifestations of preeclampsia. An intrinsic limitation is that gestational hypertension is diagnosed in retrospect, and its clinical history and course are influenced by medications and time of delivery. It is thus impossible to identify the real proportion of women who would have developed criteria for the diagnosis of preeclampsia without medical treatments or induced delivery. Further studies are therefore needed to confirm our results in a larger population, and to determine the real clinical value of C2 levels to identify women at risk of preeclampsia.
In our study, we found correlations between C2 and severity of the disease (such as proteinuria, estimated SVR, and earlier onset of hypertension) only in the preeclampsia group. In a previous study, there was a significant correlation between impaired vasodilation capacity and inhibition of NO synthases only in preeclamptic women. 16 We speculate that with preeclampsia, altered compliance levels directly reflect the effects of systemic vascular dysfunction; in women affected by gestational hypertension, the lower severity of the disease results in only partial impairment of arterial compliance and a lack of correlation between C2 and clinical signs of vascular dysfunction.
Several mechanisms may be responsible for the reduced C2 observed in the preeclampsia group; among these, lower NO bioavailability may have a relevant role. C2 levels are dependent on NO bioavailability, as previously demonstrated. 13 C2 levels are also related to NO in patients affected by cardiovascular disease, a condition known to be associated with lower NO bioavailability. In patients with preeclampsia, lower NO metabolite levels (i.e., nitrite) and less NO-dependent postischemic vasodilation suggest lower NO bioavailability. 17 Arginine and magnesium therapies prevent preeclampsia and its complications and are believed to exert their beneficial effects in part by increasing NO bioavailability. [30] [31] [32] Thus, lower NO bioavailability is a possible explanation for the lower C2 observed in the preeclampsia group.
In conclusion, the noninvasive assessment of compliance in pregnant patients with new-onset hypertension, specifically lower C2, is associated with the presence of preeclampsia and may be related to the extent of vascular Figure 3 . Small artery compliance (C2) levels at enrollment and occurrence of preeclampsia later during pregnancy. At follow-up, 6 women without proteinuria at the time of arterial compliance assessment developed preeclampsia later in pregnancy (pending preeclampsia, gray circles), whereas 19 were diagnosed with gestational hypertension (open circles). C2 in the pending preeclampsia group was lower than in the gestational hypertension group and similar to the preeclampsia group (*P < 0.01, #P < 0.05 as compared with gestational hypertension). (Horizontal shift was used to reduce circle overlap in the graph.)
alterations present with preeclampsia, although further studies are needed to confirm our findings. The serial assessment of arterial compliance in the same patients or early during pregnancy in a larger population might be pursued in future studies to identify pregnant women at risk of hypertensive complications. E
